STOCK TITAN

Medtronic plc - MDT STOCK NEWS

Welcome to our dedicated page for Medtronic plc news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic plc stock.

Medtronic plc (NYSE: MDT) is an American medical device company with its operational and executive headquarters in Minneapolis, Minnesota, and legal headquarters in Dublin, Ireland, following its acquisition of Covidien in 2015. As one of the largest medical-device companies globally, Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases.

The company’s extensive product portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. It markets these products to healthcare institutions and physicians worldwide, with international sales accounting for approximately 50% of its total revenue.

In a recent announcement on April 10, 2024, Medtronic unveiled significant advancements in artificial intelligence (AI) for endoscopic care through the launch of ColonPRO™ software for the GI Genius™ intelligent endoscopy system. This new software improves polyp detection and introduces procedural highlights to enhance physicians' workflow. The company has also entered into a collaboration with Modernizing Medicine® to integrate AI-driven data with electronic health records (EHR).

Medtronic recently reported its financial results for the fourth quarter and fiscal year 2024, showcasing a global revenue of $32.364 billion, a 3.6% increase compared to the previous year. The company's revenue growth was fueled by advancements in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.

In addition to its financial performance, Medtronic has made strides in technological innovation. The U.S. FDA approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for chronic pain treatment, demonstrating the company’s commitment to addressing unmet clinical needs and improving patient care through advanced technologies.

Medtronic remains dedicated to its mission of alleviating pain, restoring health, and extending life, driven by a global team of over 95,000 employees across 150 countries. The company continues to leverage its diverse knowledge and insatiable curiosity to deliver innovative solutions that transform lives. For more information, visit Medtronic's official website.

Rhea-AI Summary
Medtronic plc (MDT) announces positive clinical trial results for Sphere-360 catheter, showing high efficacy and safety in treating atrial fibrillation. The catheter, fully integrated with Affera™ Mapping and Ablation System, demonstrated 81.8% freedom from atrial arrhythmias after one year of follow-up. The study also highlighted 100% freedom in the sub-group treated with the optimized pulse configuration, with a treatment time of 10 minutes on average. The Sphere-360 catheter showed 96% sustained lesion durability in patients treated with the optimized pulse. The innovative design of the catheter allows for efficient energy delivery, tissue-conformable lattice tip, and compatibility with various PV anatomies. The study emphasized the catheter's safety profile with zero primary safety adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none
-
Rhea-AI Summary
Medtronic plc (MDT) announces positive results from the largest head-to-head TAVR trial, showing non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien at one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Medtronic plc unveils topline findings of a survey on women's perceptions and knowledge of heart valve disease, emphasizing the need for increased awareness, early detection, and access to appropriate care for women at risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Medtronic plc (NYSE: MDT) receives FDA approval for the Evolut™ FX+ TAVR system, enhancing valve performance with larger coronary access windows for treating symptomatic severe aortic stenosis. The system maintains market-leading valve benefits while offering improved catheter maneuverability for diverse patient anatomies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
-
Rhea-AI Summary
Medtronic (MDT) wins PTAB affirmation of patent claims in ongoing infringement lawsuit against Axonics, plans to proceed to trial on five upheld patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
Rhea-AI Summary
Medtronic plc. (NYSE: MDT) presents new data at ATTD showcasing the MiniMed™ 780G system's ability to help individuals with type 1 diabetes surpass international targets on outcome measures. The data reveals that users achieved a Time in Tight Range (TITR) of over 56%, exceeding the recommended goal of 50%. The system has shown remarkable success in improving Time in Range and moving users closer to euglycemia, enhancing overall health outcomes for people with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Medtronic plc (MDT) board authorizes $5 billion for share repurchases, consistent with its history of increasing dividends for 46 years. The dividend of $0.69 per share is payable on April 12, 2024, to shareholders of record on March 22, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
dividends earnings
-
Rhea-AI Summary
Medtronic plc (MDT) to participate in the 26th annual Barclays global healthcare conference with Karen Parkhill, the executive vice president, and CFO, answering questions on March 12, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
conferences
-
Rhea-AI Summary
Medtronic has been named one of the World's Most Ethical Companies for the second consecutive year by Ethisphere. This recognition places Medtronic among a select group of companies in the 'Healthcare Products' industry category. The annual list by Ethisphere highlights organizations that excel in business integrity, ethics, compliance, and governance practices. Medtronic's commitment to strong ethics, community focus, and patient well-being has earned them this prestigious honor, showcasing their dedication to ethical business practices and corporate citizenship.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
Rhea-AI Summary
Medtronic files a complaint with the U.S. International Trade Commission and U.S. District Court against Axonics for patent infringement related to MRI compatibility of medical devices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Medtronic plc (MDT)?

The current stock price of Medtronic plc (MDT) is $87.84 as of January 22, 2025.

What is the market cap of Medtronic plc (MDT)?

The market cap of Medtronic plc (MDT) is approximately 113.1B.

What does Medtronic plc specialize in?

Medtronic specializes in developing and manufacturing therapeutic medical devices for chronic diseases, including pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools.

Where are Medtronic’s headquarters located?

Medtronic’s operational and executive headquarters are in Minneapolis, Minnesota, while its legal headquarters are in Dublin, Ireland, following its acquisition of Covidien in 2015.

How significant are Medtronic’s international sales?

International sales account for roughly 50% of Medtronic’s total revenue.

What recent advancements has Medtronic made in AI for healthcare?

Medtronic recently launched the ColonPRO™ software for the GI Genius™ intelligent endoscopy system, enhancing AI-driven polyp detection and procedural highlights. The company also partnered with Modernizing Medicine® to integrate AI data with EHR systems.

What are Medtronic’s recent financial achievements?

Medtronic reported a global revenue of $32.364 billion for fiscal year 2024, a 3.6% increase from the previous year, driven by growth in its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios.

What new technology has Medtronic introduced for chronic pain treatment?

Medtronic introduced the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS), which the U.S. FDA approved for the treatment of chronic pain.

How many employees does Medtronic have worldwide?

Medtronic has a global team of over 95,000 employees across 150 countries.

What is Medtronic’s mission?

Medtronic's mission is to alleviate pain, restore health, and extend life.

Where can I find more information about Medtronic?

For more information about Medtronic, visit their official website at Medtronic.com.

How does Medtronic approach innovation in healthcare?

Medtronic leverages its diverse knowledge, insatiable curiosity, and commitment to helping those in need to deliver innovative technologies that transform lives, focusing on engineering extraordinary healthcare solutions.
Medtronic plc

NYSE:MDT

MDT Rankings

MDT Stock Data

113.15B
1.28B
0.26%
85.42%
0.79%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
GALWAY